The stock is a binary event play on the Phase 3 OnPrime/GOG-3076 topline data expected in 2H26. Monitor for trial enrollment completion and data readout timing; a positive result could be transformative, while a miss would likely impair the stock significantly given the single-asset nature of the company.
Price Chart
Executive Summary
Genelux reported Q2 2026 net loss of $0.21 per share, slightly below the $0.20 consensus estimate. The pre-revenue clinical-stage biotech highlighted $18.7M cash runway into Q1 2027 and reiterated Phase 3 ovarian cancer topline data expected in 2H26, which is the primary catalyst. The earnings miss is negligible for a pre-revenue company; the stock will move on the Phase 3 data readout, not quarterly financials.
Key Financial Metrics
Key Facts
- Net loss of $9.5M ($0.21/share) vs $7.5M ($0.20/share) in Q2 2025, slightly below consensus of $0.20.
- Cash, equivalents, marketable securities, and restricted cash of $18.7M as of June 30, 2026, expected to fund operations into Q1 2027.
- Phase 3 OnPrime/GOG-3076 registrational trial topline data for Olvi-Vec in platinum-resistant/refractory ovarian cancer expected in 2H26.
- R&D expenses increased to $6.5M from $4.8M YoY, driven by Phase 3 trial costs.
- Weighted-average shares outstanding increased to 44.96M from 37.95M YoY, reflecting dilution.
Financial Impact
Net loss of $9.5M, cash burn rate ~$3.2M/month based on $18.7M cash runway into Q1 2027 (approx. 6 months).
Risk Factors
- Phase 3 trial failure or delay would be catastrophic for a single-asset biotech.
- Cash runway only into Q1 2027; likely need for dilutive financing if data readout is delayed or negative.
- No revenue and increasing R&D spend; operating losses will continue to widen.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344971 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | Insider Cluster | $2.52 $2.53 | ▼ −0.40% | ▼ −1.52% | $1.92 (+23.81%) |
Aug 13, 2026 10w ago | Press Release | $2.74 $2.54 | ▼ −7.30% | ▼ −5.31% | $1.92 (−29.93%) |
Jun 4, 2026 20w ago | Insider Cluster | $2.93 $3.02 | ▲ +3.07% | ▲ +1.21% | $1.92 (−34.47%) |
May 11, 2026 24w ago | Insider Cluster | $2.90 $2.98 | ▲ +2.76% | ▲ +3.06% | $1.92 (−33.79%) |
Apr 29, 2026 25w ago | DEFA14A | $2.50 $3.06 | ▲ +22.40% | ▲ +16.94% | $1.92 (−23.20%) |
Mar 24, 2026 31w ago | Insider Cluster | $2.42 $2.54 | ▲ +4.96% | ▼ −3.94% | $1.92 (−20.66%) |
Mar 19, 2026 31w ago | Press Release | $2.40 $2.65 | ▲ +10.42% | ▲ +1.10% | $1.92 (−20.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers